Lv1
16 积分 2025-08-19 加入
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
2天前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
2个月前
已完结
Exploring the next generation of antibody–drug conjugates
3个月前
已完结
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
4个月前
已完结
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
4个月前
已完结
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
4个月前
已完结
Evolution of low HER2 expression between early and advanced-stage breast cancer
4个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
4个月前
已完结
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
5个月前
已完结
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
5个月前
已完结
皖公网安备34019202002308
